Applied Therapeuticsの空売り状況は、投資家がApplied Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Applied Therapeutics (NASDAQ:APLT) 株価情報, 空売り情報

Applied Therapeutics

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics Inc

Deutsche Bank analyst Sidney Ho maintains KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Buy and raises the price target from $725 to $850.

News

Price Target

Analyst Ratings

KLAC

Deutsche Bank Maintains Buy on KLA, Raises Price Target to $850

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and raises the price target from $180 to $190.

AXSM

HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $190

Needham analyst Quinn Bolton reiterates Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) from Hold to Hold.

Reiteration

INTC

Needham Reiterates Hold on Intelto Hold

B of A Securities analyst Jason Kupferberg maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Neutral and raises the price target from $331 to $363.

B of A Securities Maintains Neutral on Visa, Raises Price Target to $363

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Benjamin Hartford downgraded the rating for United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) from Outperform to Neutral and lowered the price target from $160 to $130. UPS shares closed at $114.90 on Thursday. <a href="https://www.benzinga.com/quote/UPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Neil Mehta downgraded Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) from Neutral to Sell and slashed the price target from $54 to $45. Occidental Petroleum shares closed at $48.92 on Thursday. <a href="https://www.benzinga.com/quote/OXY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Michael Lavery downgraded the rating for The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) from Neutral to Underweight and cut the price target from $153 to $120. Hershey shares closed at $152.14 on Thursday. <a href="https://www.benzinga.com/quote/HSY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Jessica Reif Cohen downgraded Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) from Buy to Neutral and lowered the price target from $50 to $38. Comcast shares closed at $33.25 on Thursday. <a href="https://www.benzinga.com/quote/CMCSA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Neal Dingmann downgraded the rating for Murphy Oil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) from Buy to Hold and lowered the price target from $42 to $31. Murphy Oil shares closed at $27.47 on Thursday. <a href="https://www.benzinga.com/quote/MUR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OXY stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43335398/wall-streets-most-accurate-analysts-spotlight-on-3-risk-off-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Risk Off Stocks Delivering High-Dividend Yields</a></li>
</ul>

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

CMCSA

This Occidental Petroleum Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) with a Buy and maintains $110 price target.

HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target

B of A Securities analyst Ken Hoexter maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Buy and lowers the price target from $150 to $133.

B of A Securities Maintains Buy on United Parcel Service, Lowers Price Target to $133

Needham analyst Joseph Stringer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Hold to Hold.

VRTX

Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold

23andMe Holding Released New Polygenic Risk Score Report On The Genetics Of Osteoporosis For 23andMe+ Premium Members

WIIM

ABBV

AbbVie shares are trading higher following better-than-expected Q4 financial results.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) with a Buy and maintains $55 price target.

MNMD

HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $55 Price Target

A new player in the AI arena, DeepSeek, has unveiled an open-source language model, R1, that experts say is a game-changer in efficiency, raising questions about the <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43244653/bitcoin-ethereum-solana-crash-heres-why-chinas-low-cost-ai-model-deepseek-may-be-to-blame">future of AI development.</a>
<h2 class="wp-block-heading">The DeepSeek Effect</h2>
Developed for under $6 million, DeepSeek&#8217;s R1 has not only outperformed established competitors in several tests but has also called into question the established big-spending approach prevalent in Silicon Valley. 
This development has triggered a mix of optimism about democratized AI and fears of an AI stock bubble bursting, sending ripples throughout financial markets.
&#8220;Another DeepSeek is hiding in plain sight,&#8221; said Roi Ginat, CEO of Endless AI, a multimodal AI company, highlighting DeepSeek's influence in making impactful AI with limited resources. 
Ginat&#8217;s own company, EndlessAI, has been working on efficient video processing, echoing DeepSeek's stand to using LLMs in practical, cost-effective ways. 
Ginat told Benzinga that EndlessAI provides the tools to make existing models work smarter by using proprietary video transfer optimization which enables massive cost reduction for video processing, adding that this is complementary, not competitive, with what DeepSeek is doing.
Speaking with Benzinga, Satya Nitta, CEO of Emergence AI, an AI orchestration company, echoed the sentiment, calling DeepSeek R1 a &#8220;meaningful advance in broadening access to AI reasoning.&#8221; 
Nitta emphasized the importance of open-source solutions that are not only trusted but also scalable and adaptable to evolving needs.
Matthew Putman, CEO of Nanotronics, an industrial AI company, told Benzinga that DeepSeek&#8217;s achievement demonstrates that &#8220;it is possible to do more with less,&#8221; suggesting that resource constraints may fuel innovation. 
Putman sees these developments as essential for broader adoption of AI for industries beyond just text generation, stressing it's critical for advancing semiconductor production, which makes AI technology possible.
Mitesh Agrawal, CEO of Positron, an AI hardware company, pointed to DeepSeek&#8217;s success as evidence that &#8220;inference-time compute is the new scaling factor&#8221; in AI development, delivering real results with optimized systems. 
Agrawal told Benzinga that performance per dollar and performance per watt are critical to make the best AI models accessible.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43356514/helix-debuts-ai-index-perpetual-market">Helix Debuts AI Index Perpetual Market, Bridging Crypto And Traditional Equities On-Chain</a>
<h2 class="wp-block-heading">Is DeepSeek A Cause For Concern?</h2>
However, concerns also accompany this disruptive innovation.
Speaking with Benzinga, Pukar Hamal, CEO of SecurityPal, an AI-enhanced security review company, warned about the security and regulatory implications of an "open-source" model with unknown alignment. 
Hamal highlighted the &#8220;gas law&#8221; of computing, whereby cheaper compute expands markets, but also stressed the need for guardrails to protect the public and maintain compliance.
These concerns translated into market jitters on the day DeepSeek news first broke.
The Nasdaq Composite dropped 2.7% on Monday, the S&amp;P 500 slid 1.6% and the Dow Jones Industrial Average dipped 0.1% following the DeepSeek announcement.
The announcement of a new low-cost, high-performance open source AI model that competes with existing proprietary AI systems also drove volatility in the cryptocurrency market. 
Crypto markets also took a hit, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) falling 5.5% and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) dropping 7% on Monday before recovering.
Other major altcoins also experienced significant losses, as traders grappled with the potential implications of DeepSeek&#8217;s emergence.
On Monday, altcoins like Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) were down 11%, 3.5%, 9% and 8.5%, respectively.
<h2 class="wp-block-heading">What&#8217;s Next For DeepSeek</h2>
DeepSeek's disruptive impact is already rippling through financial markets. 
The sharp declines in AI-related stocks and cryptocurrencies suggest that investors are reassessing the sustainability of current AI valuations. 
Analysts warn that DeepSeek's ability to deliver high-performance AI at a fraction of traditional costs may force industry leaders to rethink their strategies.
Moreover, experts believe DeepSeek's approach could reshape the $25 billion computer vision market and redefine the scalability of AI applications. 
As companies continue to push the boundaries of multimodal AI, the industry appears poised for a shift toward leaner, more efficient AI models that can thrive outside the confines of billion-dollar research labs.
In the face of this transformation, the question remains: will legacy AI firms adapt to the new paradigm, or will DeepSeek's breakthrough mark the beginning of a broader industry upheaval?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43351797/grayscale-seeks-sec-approval-to-convert-xrp-trust-into-exchange-traded-fund">Grayscale Seeks SEC Approval To Convert XRP Trust Into Exchange-Traded Fund</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BNB

$BTC

$DOGE

$ETH

$SOL

Experts Say DeepSeek Proves High-Performance AI Possible Without Silicon Valley's Spending

Guidance

AbbVie Sees FY25 Adj. EPS $12.12-$12.32 vs $10.08 Est.; Reaffirms Long-Term Revenue Growth Outlook of High Single-Digit CAGR Through 2029

YMAB

Y-mAbs Therapeutics Says It Will Present Preclinical And Translational Pharmacokinetics Data Of GD2-SADA In A Poster At Society Of Nuclear Medicine & Molecular Imaging Mid-winter And American College Of Nuclear Medicine Annual Meeting

Hitachi (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HTHIY#OTC">HTHIY</a>) reported its Q3 earnings results on Friday, January 31, 2025 at 07:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Hitachi missed estimated earnings by -9.0%, reporting an EPS of $0.4 versus an estimate of $0.44.
Revenue was up $903.00 million from the same period last year.
<h3>Historical Earnings Summary</h3>
In the previous quarter, the company missed on EPS by $0.07, resulting in a 5.0% increase change in the share price the following day.
Here's a look at Hitachi's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.41</td>
<td>0.05</td>
<td>0.33</td>
<td>0.34</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.34</td>
<td>0.49</td>
<td>1.02</td>
<td>0.64</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>15.82B</td>
<td>12.27B</td>
<td>15.53B</td>
<td>13.49B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>15.68B</td>
<td>14.19B</td>
<td>18.68B</td>
<td>15.28B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Hitachi management provided guidance for FY 2024, expecting earnings between $0.91 and $0.91 per share.
To track all earnings releases for Hitachi <a href="https://www.benzinga.com/quote/HTHIY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

HTHIY

Earnings Summary: Hitachi Q3

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported quarterly earnings of $2.16 per share which beat the analyst consensus estimate of $2.11 by 2.37 percent. This is a 22.58 percent decrease over earnings of $2.79 per share from the same period last year. The company reported quarterly sales of $15.102 billion which beat the analyst consensus estimate of $14.827 billion by 1.85 percent. This is a 5.60 percent increase over sales of $14.301 billion the same period last year.

Earnings Beats

AbbVie Q4 2024 Adj. EPS $2.16 Beats $2.11 Estimate, Sales $15.102B Beat $14.827B Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) with a Buy and maintains $9 price target.

LCTX

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

First BanCorp. Reveals Strategic Reorganization Aligned With Corporate Succession Plan Aimed At Improving Operational Efficiency, Enhancing Customer Experience, And Driving Business Transformation To Align Resources For Growth

HC Wainwright &amp; Co. analyst Edward White reiterates Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) with a Buy and maintains $18 price target.

VALN

HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $18 Price Target

Samsung Electronics Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) <a target="_blank" href="https://www.benzinga.com/topic/samsung" rel="noreferrer noopener">reported fourth-quarter revenue</a> growth of 12% year-on-year to 75.8 trillion Korean won ($52.2 billion).
Operating profit declined by 30% Q/Q to 6.5 trillion Korean won due to soft market conditions, especially for IT products, and higher R&amp;D expenditures.
The DS Division (encompassing Memory and S.LSI / Foundry) posted 30.1 trillion Korean won in revenue (versus 21.7 trillion Korean won Y/Y) backed by a higher blended DRAM average selling price (ASP) due to the increased sales of high-bandwidth memory (HBM) and high-density <a target="_blank" href="https://www.samsung.com/global/ir/financial-information/earnings-release/" rel="noreferrer noopener">DDR5 for servers</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43165472/samsung-taps-google-ai-qualcomm-tech-for-galaxy-s25-to-rival-apples-iphone" rel="noreferrer noopener">Samsung Taps Google AI, Qualcomm Tech for Galaxy S25 to Rival Apple&#8217;s iPhone</a>
The division reported 2.9 trillion Korean won in operating profit (versus a loss of (2.2) trillion Korean won Y/Y).
Samsung Display Corp Division, posted 8.1 trillion Korean won in revenue (versus 9.7 trillion Korean won Y/Y). The division reported 0.9 trillion Korean won in operating profit (versus 2.0 trillion Korean won Y/Y) due to sluggish smartphone demand and rising competition for the mobile display business.
The Mobile eXperience (MX) and Networks businesses posted 25.8 trillion Korean won in revenue (versus 25.0 Korean won Y/Y). The division reported 2.1 trillion Korean won in operating profit (versus 2.7 trillion Korean won Y/Y).
The quarterly capex was 17.8 trillion Korean won, with 16 trillion Korean won allocated to the DS Division and 1 trillion Korean won to SDC.
While overall earnings improvement may be limited in the first quarter of 2025 due to weakness in the semiconductors business, the company aims to pursue growth through increased sales of smartphones with differentiated AI experiences and premium products in the Device eXperience (DX) Division.
For 2025, the company plans to enhance technological and product advantages in AI, meet future demand for high-value-added products, and drive sales growth in premium segments.
Samsung, in a preliminary earnings report, flagged sluggish demand for conventional chips used in personal computers and mobile phones weighed on its memory business, with earnings also dented by rising R&amp;D costs and early investments in expanding advanced-chip processing capability, the Wall Street Journal <a target="_blank" href="https://www.wsj.com/business/earnings/samsungs-net-profit-beats-consensus-but-chip-woes-weigh-cad40447?mod=tech_lead_pos1" rel="noreferrer noopener">reports</a>.
SK Hynix has left Samsung behind in HBM, Eric Ross of Cascend Securities, <a target="_blank" href="https://www.cnbc.com/2025/01/31/samsung-fourth-quarter-profit-falls-short-of-estimates-as-ai-demand-remains-strong.html" rel="noreferrer noopener">told</a> CNBC. Micron Technology, Inc also gained ground, Ross told. PC and smartphone DRAM markets are under price pressure, he added.
Nabila Popal of IDC told CNBC that Samsung&#8217;s share of the premium market has inched closer to market leader Apple Inc thanks to the former&#8217;s Galaxy S24 series featuring Galaxy AI.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/media/25/01/43352019/amazon-cuts-more-jobs-in-cost-saving-push-report" target="_blank" rel="noreferrer noopener">Amazon Cuts More Jobs in Cost-Saving Push: Report</a></li>
</ul>
Image via Shutterstock.

Equities

Media

SSNLF

Samsung Q4 Earnings: 12% Revenue Growth, Closes Gap With Apple In Premium Phones, Eyes AI-Powered Growth In 2025

Applied Therapeutics appoints Johnson as Executive Chairman, CEO steps down

The latest announcement is out from Applied Therapeutics ( ($APLT) ). Applied Therapeutics, Inc. has appointed John H. Johnson as Executive Chairma...

Applied Therapeutics Faces Leadership Changes and Regulatory Hurdles

RBC Capital analyst Brian Abrahams lowered the firm's price target on Applied Therapeutics (APLT) to $1.50 from $4 and keeps a Sector Perform ratin...

Applied Therapeutics price target lowered to $1.50 from $4 at RBC Capital

Applied Therapeutics (APLT – Research Report) received a Hold rating and price target from William Blair analyst Sami Corwin today. The company's s...

William Blair downgrades Applied Therapeutics (APLT) to a Hold

William Blair downgraded Applied Therapeutics (APLT) to Market Perform from Outperform. Published first on TheFly – the ultimate source for real-ti...

Applied Therapeutics downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Applied Therapeutics (APLT) to Market Perform from Outperform without a price target While the management turnover "was a ...

William Blair downgrades Applied Therapeutics on revenue uncertainty

Check out this morning's top movers from around Wall Street, compiled by The Fly.&nbsp; HIGHER – Despegar.com&nbsp;(DESP) up 33% after Prosus annou...

Morning Movers: Despegar surges following deal to be acquired by Prosus

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Members of the Nordstrom family ...

Nordstrom family to take chain private: Morning Buzz

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), Vertex ...

Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)

ACRS

APLT

AVXL

DESP

ENGN

EXEL

GCMG

HNDAF

IIPR

LAES

MEOBF

MESO

MSTR

NSANF

NSANY

ORKA

PLYA

PONY

RGTI

SMTI

VVOS

WULF

XELB

Press Releases

APLT Deadline Approaching on February 18, 2025: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Class Action Lawsuit Deadline

Legal

APLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Applied Therapeutics, Nextracker, and Transocean and Encourages Investors to Contact the Firm

The Gross Law Firm Reminds Applied Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025 - APLT

Penny Stocks

Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Applied Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – APLT

APLT INVESTOR ALERT: Kirby McInerney LLP Notifies Applied Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLT

Shareholders that lost money on Applied Therapeutics, Inc.(APLT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

APLT FRAUD ALERT: Applied Therapeutics Sued for Securities Fraud after Stock Drops 80% – Investors Urged to Contact BFA Law by February 18 Deadline (NASDAQ:APLT)

Comments

Applied Therapeutics

空売り

Applied Therapeutics (NASDAQ:APLT) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル